All In Biotech

Investigational drug · Phase 2

WSD0922-FU

Also called: WSD0922

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non Small Cell Lung Cancer (NSCLC), EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

3

3 still active

All registered trials

6

Any phase or sponsor naming "WSD0922-FU"

First trial start

2024

Sep 4, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "WSD0922-FU", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Non Small Cell Lung Cancer (NSCLC)
  • EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
  • Non Small Cell Lung Cancer

Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "WSD0922-FU" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Also in development for Non Small Cell Lung Cancer (NSCLC)

  • JSKN033Phase 34 trials

    Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Cervical Cancer, Recurrent or Metastatic Cervical Cancer, Advanced Malignant Tumors

  • LS301-ITPhase 22 trials

    Integro Theranostics · Non Small Cell Lung Cancer (NSCLC), Breast Cancer, DCIS

  • AP203Phase 21 trial

    AP Biosciences Inc. · Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.